钠-葡萄糖协同转运蛋白 2（SGLT2）抑制剂在心力衰竭中的应用：早期起始以实现快速临床获益。
SGLT2 Inhibitors in Heart Failure: Early Initiation to Achieve Rapid Clinical Benefits.
机构信息
Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. Electronic address: https://twitter.com/NealDixit.
Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA; Division of Cardiology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA; Division of Cardiology, Veteran Affairs Greater Los Angeles Healthcare System, Los Angeles, CA, USA. Electronic address: https://twitter.com/boback.
出版信息
Heart Fail Clin. 2022 Oct;18(4):587-596. doi: 10.1016/j.hfc.2022.03.003.
Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are a recent addition to the pillars of medical therapy for heart failure (HF) with reduced ejection fraction, all of which improve quality of life, morbidity, and mortality. These benefits are evident within the first 30 days of initiation. This review discusses the rationale for SGLT2i initiation in simultaneous or in rapid sequence with other guideline-directed medical therapy (GDMT). We also discuss SGLT2i use and early benefits in HF patients with an ejection fraction greater than 40%.
钠-葡萄糖共转运蛋白 2 抑制剂（SGLT2i）是射血分数降低的心力衰竭（HF）治疗支柱的最新补充，它们都能改善生活质量、发病率和死亡率。这些益处在开始治疗的 30 天内就显现出来。这篇综述讨论了 SGLT2i 与其他指南指导的药物治疗（GDMT）同时或快速序贯起始的原理。我们还讨论了 SGLT2i 在射血分数大于 40%的 HF 患者中的使用和早期益处。
Zotero 插件